Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$10.48
+2.2%
$10.39
$3.52
$23.40
$478.70M0.851.73 million shs994,418 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.13
-4.5%
$1.03
$0.40
$2.55
$171.72M1.112.13 million shs3.74 million shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.61
-4.7%
$1.65
$1.40
$7.88
$71.47M1.69339,751 shs372,214 shs
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$0.27
+24.0%
$0.46
$0.08
$3.55
$7.95M7.6711.10 million shs201.95 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
+2.24%-4.81%-19.57%-27.52%+74.96%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-4.48%+3.40%+200.00%+212.68%+21.71%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-4.73%-2.42%-9.04%-5.29%-74.80%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
+24.02%+12.50%-53.53%-79.85%-90.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
1.8159 of 5 stars
3.52.00.00.02.00.80.6
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.2545 of 5 stars
3.51.00.04.73.12.51.3
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.9438 of 5 stars
2.03.00.00.03.12.51.3
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
0.424 of 5 stars
0.02.00.00.03.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
3.00
Buy$35.50238.74% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33150.39% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.0024.22% Upside
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CAPR, EPIX, CTMX, and IXHL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$31.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/14/2025
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
4/14/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50
3/20/2025
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
3/17/2025
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00 ➝ $77.00
3/7/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00
3/7/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/4/2025
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00 ➝ $77.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
$17.36M27.57N/AN/A$0.73 per share14.36
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$147.56M1.16N/AN/A($0.71) per share-3.00
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.68 per shareN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$98K81.09N/AN/A$0.05 per share5.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$22.29M-$1.42N/AN/AN/A-146.86%-112.95%-57.00%8/6/2025 (Estimated)
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$570K$0.4812.53N/AN/A10.96%-41.47%8.11%8/14/2025 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-24.61%-23.87%8/4/2025 (Estimated)
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-$18.46M-$1.21N/AN/AN/A-289.30%-154.96%N/A

Latest CAPR, EPIX, CTMX, and IXHL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q3 2025
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-$0.46-$0.24+$0.22-$0.20$0.16 million$0.10 million
5/13/2025Q1 2025
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$0.33-$0.53-$0.20-$0.53$3.16 million$2.73 million
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
3/19/2025Q4 2024
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
-$0.31-$0.16+$0.15-$0.16$9.87 million$11.13 million
3/6/2025Q4 2024
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.23$0.22+$0.45$0.22$13.53 million$38.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A
4.19
4.19
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.04
1.04
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
33.12
33.12
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
2.47
1.80
1.65

Institutional Ownership

CompanyInstitutional Ownership
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
21.68%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
0.43%

Insider Ownership

CompanyInsider Ownership
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
10.50%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
7.00%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
26.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Capricor Therapeutics Inc stock logo
CAPR
Capricor Therapeutics
N/A45.68 million40.01 millionOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million72.78 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
329.43 million13.12 millionNot Optionable

Recent News About These Companies

Cannabis Stocks To Follow Today - May 19th
Top Cannabis Stocks To Follow Now - May 20th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$10.48 +0.23 (+2.24%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$10.52 +0.04 (+0.43%)
As of 05/27/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.13 -0.10 (-4.48%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.13 +0.00 (+0.23%)
As of 05/27/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.61 -0.08 (-4.73%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.67 +0.06 (+3.73%)
As of 05/27/2025 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Incannex Healthcare stock logo

Incannex Healthcare NASDAQ:IXHL

$0.27 +0.05 (+24.02%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.25 -0.02 (-7.41%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.